These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16236860)

  • 1. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Matera MG; Donnarumma G; Tufano MA; Sanduzzi A; Marchetti F; Blasi F
    Chest; 2005 Oct; 128(4):2093-8. PubMed ID: 16236860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin pharmacokinetics in adult cystic fibrosis.
    Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
    Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE; Golden JA; McIver M; Little E; Zurlinden E
    Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections.
    Guillaume M; Garraffo R; Bensalem M; Janssen C; Bland S; Gaillat J; Bru JP
    Med Mal Infect; 2012 Sep; 42(9):414-20. PubMed ID: 22944286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
    Nicolle L; Duckworth H; Sitar D; Bryski L; Harding G; Zhanel G
    Int J Antimicrob Agents; 2008 Mar; 31(3):287-9. PubMed ID: 18155885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE; Golden JA; McIver M; Zurlinden E
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
    Nicolau DP; Sutherland C; Winget D; Baughman RP
    Pulm Pharmacol Ther; 2012 Feb; 25(1):94-8. PubMed ID: 22210007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Di Perna F; Boveri B; Di Marco F; Diamare F; Centanni S
    J Chemother; 2000 Jun; 12(3):216-22. PubMed ID: 10877516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
    Scaglione F; Mouton JW; Mattina R; Fraschini F
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ
    J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
    Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
    Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Corrado M
    JAMA; 1998 Jan; 279(2):125-9. PubMed ID: 9440662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
    Albarellos GA; Ambros LA; Landoni MF
    J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue and serum levofloxacin concentrations in diabetic foot infection patients.
    Oberdorfer K; Swoboda S; Hamann A; Baertsch U; Kusterer K; Born B; Hoppe-Tichy T; Geiss HK; von Baum H
    J Antimicrob Chemother; 2004 Oct; 54(4):836-9. PubMed ID: 15375105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
    Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
    Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.